Update shared on23 Aug 2025
Fair value Increased 6.26%The increase in ALK-Abelló’s analyst price target is primarily driven by a modest upward revision in consensus revenue growth forecasts, while net profit margins remain steady, resulting in a new fair value estimate of DKK192.33 per share.
What's in the News
- ALK-Abelló raised its 2025 revenue growth guidance to 12-14% (from 9-13%) in local currencies, supported by strong adrenaline autoinjector and tablet sales in Europe and North America, and will allocate additional funds to strategic growth investments.
- NICE recommended ALK's tree pollen tablet ITULAZAX for NHS reimbursement in England, Wales, and Northern Ireland, following recent approval of ACARIZAX, expanding access to sublingual allergy immunotherapy in the UK; submissions for paediatric and grass tablet approvals are planned.
- MHRA approved EURneffy, the first adrenaline nasal spray for anaphylaxis, in the UK, offering a needle-free, reliable emergency treatment for adults and children ≥30 kg, with launch expected soon.
- EURneffy 2 mg adrenaline nasal spray was launched in Germany, representing a significant innovation in anaphylaxis emergency treatment with a longer shelf life and superior temperature stability compared to traditional auto-injectors; 1 mg dosage for lighter children is under EU regulatory review.
- At the EAACI 2025 Congress, ALK presented new data highlighting innovation in anaphylaxis management (notably EURneffy), paediatric respiratory allergies, and advances in peanut allergy treatment.
Valuation Changes
Summary of Valuation Changes for ALK-Abelló
- The Consensus Analyst Price Target has risen from DKK181.00 to DKK192.33.
- The Consensus Revenue Growth forecasts for ALK-Abelló has risen slightly from 12.9% per annum to 13.5% per annum.
- The Net Profit Margin for ALK-Abelló remained effectively unchanged, moving only marginally from 19.78% to 20.13%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.